Condensed Consolidated Balance Sheets - USD ($)	Mar. 31, 2016	Jun. 30, 2015
Current Assets:
Cash and cash equivalents	$ 11,209,309	$ 13,452,775
Marketable securities	50,369,863	86,165,532
Accounts receivable, net of allowance for doubtful accounts of $85,254 at March 31, 2016 and $54,177 at June 30, 2015	590,820	345,627
Inventory	170,680	584,424
Other receivables	270,817	857,068
Prepaid expenses	1,562,352	1,136,103
Other current assets	270,146	945,673
Total current assets	64,443,987	103,487,202
Property and equipment, net of accumulated depreciation of $28,396,052 and $27,891,272 at March 31, 2016 and June 30, 2015, respectively	3,167,554	2,241,838
Other long-term assets	30,000	50,566
Total Assets	67,641,541	105,779,606
Current Liabilities:
Accounts payable and accrued expenses	13,535,994	11,808,223
Deferred revenues	265,692	271,667
Total current liabilities	13,801,686	12,079,890
Convertible senior notes – net of unamortized debt issuance costs of $2,282,057 at March 31, 2016 and $3,375,423 at June 30, 2015	97,171,943	96,624,577
Other liabilities	$ 1,674,397	$ 1,599,760
Commitments and Contingencies
Stockholders' Deficit:
Common stock, $.01 par value; authorized 155,000,000 shares; issued 94,836,015 shares and outstanding 94,546,578 shares at March 31, 2016; and issued 94,546,578 shares and outstanding 94,511,853 shares at June 30, 2015	$ 948,359	$ 945,465
Capital contributed in excess of par	307,907,709	305,229,354
Treasury stock, at cost, 34,725 shares at March 31, 2016 and at June 30, 2015	(458,370)	(458,370)
Accumulated deficit	(352,603,921)	(309,468,004)
Accumulated other comprehensive loss	(113,868)	(161,092)
Total Immunomedics, Inc. stockholders' deficit	(44,320,091)	(3,912,647)
Noncontrolling interest in subsidiary	(686,394)	(611,974)
Total stockholders’ deficit	(45,006,485)	(4,524,621)
Total Liabilities and Stockholders' Deficit	$ 67,641,541	$ 105,779,606